Frequently Asked Questions about Mesoblast Limited (MESO)

Name: Mesoblast Limited (MESO) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Mesoblast Limited (MESO) do?

Accepted Answer

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and ...

Question 2

Is Mesoblast Limited (MESO) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of MESO reveals an Altman Z-Score of 3.52 and a Piotroski F-Score of 5/9. These metrics, combined with its 5-year revenue trend ($0.02B most recent), help investors decide if MESO fits their risk profile.

Question 3

What is the current P/E ratio for MESO?

Accepted Answer

As of the latest trading session, Mesoblast Limited (MESO) has a trailing P/E ratio of -22.43.

Question 4

Who is the CEO of Mesoblast Limited?

Accepted Answer

The current Chief Executive Officer of Mesoblast Limited is Silviu Itescu.

Question 5

What was MESO's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Mesoblast Limited reported annual revenues of $0.02B (2025), $0.01B (2024), $0.01B (2023), $0.01B (2022), $0.01B (2021) respectively.

Question 6

Does MESO pay a dividend?

Accepted Answer

Mesoblast Limited does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does MESO have?

Accepted Answer

In its latest reporting period, Mesoblast Limited generated $-0.05B in Free Cash Flow against a total debt load of $N/A.

Question 8

What is the Price-to-Book (P/B) ratio of Mesoblast Limited?

Accepted Answer

The Price-to-Book (P/B) ratio for Mesoblast Limited (MESO) is currently 3.05.

Question 9

What is the Price-to-Sales (P/S) ratio of MESO?

Accepted Answer

Based on trailing twelve-month data, Mesoblast Limited (MESO) trades at a Price-to-Sales (P/S) ratio of 113.59.

Question 10

What is Mesoblast Limited's Return on Equity (ROE)?

Accepted Answer

Mesoblast Limited (MESO) has a Return on Equity (ROE) of -14.02%, representing its profitability relative to shareholder equity.